NEW YORK (TheStreet) -- Ohr Pharmaceuticals (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.
The stock plunged Tuesday after it reported results of its phase II study on its Squalamine eye drop. For more on that, read TheStreet's Adam Feuerstein's article here.
Ohr closed up 35.43%, or $2.59, to $9.90 on Thursday. More than 5.7 million shares changed hands, compared to the average volume of 401,319.